(Q37402055)

20 August 2017

1 reference

title

Biomarkers for tuberculosis disease activity, cure, and relapse. (English)

1 reference

20 August 2017

0 references

0 references

8

1 reference

20 August 2017

Shreemanta Parida

7

0 references

author name string

Robert S Wallis

1

1 reference

20 August 2017

T Mark Doherty

2

1 reference

20 August 2017

Phillip Onyebujoh

3

1 reference

20 August 2017

Mahnaz Vahedi

4

1 reference

20 August 2017

Hannu Laang

5

1 reference

20 August 2017

Ole Olesen

6

1 reference

20 August 2017

1 March 2009

1 reference

Lancet Infectious Diseases

20 August 2017

1 reference

20 August 2017

9

1 reference

20 August 2017

3

1 reference

20 August 2017

162-172

1 reference

The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis

20 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

HIV-1 load quantitation: a 17-year perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in south India.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 month

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Acquired rifamycin resistance: pharmacology and biology

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Diagnosis of pulmonary tuberculosis in young children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Pathology and causes of death in a series of human immunodeficiency virus-positive and -negative pediatric referral hospital admissions in Botswana

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Induction of the antigen 85 complex of Mycobacterium tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Predicting the outcome of therapy for pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

The scent of Mycobacterium tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Volatile biomarkers of pulmonary tuberculosis in the breath.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Neopterin, beta 2-microglobulin, and acute phase proteins in HIV-1-seropositive and -seronegative Zambian patients with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Elevated interleukin-2 receptor level in patients with active pulmonary tuberculosis and the changes following anti-tuberculosis chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Serum C-reactive protein and detection of tuberculosis in persons co-infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Predicting deterioration of treated tuberculosis by corticosteroid reserve and C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Dynamic Antigen-specific T-Cell Responses after Point-Source Exposure toMycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Evaluation of Human Antimycobacterial Immunity Using Recombinant Reporter Mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Novel human in vitro system for evaluating antimycobacterial vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Failure to control growth of mycobacteria in blood from children infected with human immunodeficiency virus and its relationship to T cell function

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Reconstitution of antimycobacterial immune responses in HIV-infected children receiving HAART.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

A single dose of vitamin D enhances immunity to mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

A whole blood bactericidal assay for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Lack of activity of orally administered clofazimine against intracellular Mycobacterium tuberculosis in whole-blood culture

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Whole Blood Bactericidal Activity during Treatment of Pulmonary Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Blood and urine samples as useful sources for the direct detection of tuberculosis by polymerase chain reaction.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

PCR-based detection of the Mycobacterium tuberculosis complex in urine of HIV-infected and uninfected pulmonary and extrapulmonary tuberculosis patients in Burkina Faso.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Identification of HIV patients with active pulmonary tuberculosis using urine based polymerase chain reaction assay

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Molecular differentiation of Mycobacterium tuberculosis strains without IS6110 insertions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Clinical and radiological features in relation to urinary excretion of lipoarabinomannan in Ethiopian tuberculosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Detection of Mycobacterium tuberculosis antigens in urinary proteins of tuberculosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Combined Use of Serum and Urinary Antibody for Diagnosis of Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Identification and characterization of Mycobacterium tuberculosis antigens in urine of patients with active pulmonary tuberculosis: an innovative and alternative approach of antigen discovery of useful microbial molecules.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Identification of Mycobacterium tuberculosis ornithine carboamyltransferase in urine as a possible molecular marker of active pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Immune activation, allergic drug toxicity and mortality in HIV-positive tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Serum interleukin-2 and neopterin levels as useful markers for treatment of active pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Biomarkers for TB treatment response: challenges and future strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Elevated levels of circulating adhesion molecules in patients with active pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Changes of plasma interleukin-1 receptor antagonist, interleukin-8 and other serologic markers during chemotherapy in patients with active pulmonary tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

The non-immune inflammatory response: serial changes in plasma iron, iron-binding capacity, lactoferrin, ferritin and C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Interferon-gamma and interleukin-12 pathway defects and human disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Correlates of protective immunity to Mycobacterium tuberculosis in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Depressed T‐Cell Interferon‐γ Responses in Pulmonary Tuberculosis: Analysis of Underlying Mechanisms and Modulation with Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Relationship between whole-blood interferon-gamma responses and the risk of active tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Ex vivo cytokine mRNA levels correlate with changing clinical status of ethiopian TB patients and their contacts over time

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

The 6-kilodalton early secreted antigenic target-responsive, asymptomatic contacts of tuberculosis patients express elevated levels of interleukin-4 and reduced levels of gamma interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

In vivo and in vitro studies of a novel cytokine, interleukin 4delta2, in pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Differential expression of interleukin-4 (IL-4) and IL-4 delta 2 mRNA, but not transforming growth factor beta (TGF-beta), TGF-beta RII, Foxp3, gamma interferon, T-bet, or GATA-3 mRNA, in patients with fast and slow responses to antituberculosis tre

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

TB chemotherapy: antagonism between immunity and sterilization.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Bacillus Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970042-8

7 January 2021

10.1016/S1473-3099(09)70042-8

Identifiers

DOI

1 reference

20 August 2017

1 reference